Alexion Pharmaceuticals, Inc. (ALXN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alexion Pharmaceuticals, Inc. (ALXN)

ALXN 182.50

0.0%

Jul 28 4:00 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: tnsaf	12/8/2008 11:27:19 PM
	of 824

Alexion: Blood disorder drug does well in Japan Monday December 8, 4:24 pm ET Alexion Pharmaceuticals says blood disorder treatment Soliris does well in Japanese study CHESHIRE, Conn. (AP) -- Alexion Pharmaceuticals Inc. said Monday a study of its drug Soliris in the treatment of Japanese patients suffering from a rare, life-threatening blood disorder showed several positive results. Patients saw improvement in kidney function and reductions in the destruction of red blood cells, anemia, transfusion dependence and fatigue, the company said in a statement. Alexion said the results are similar to those from late-stage studies conducted in the United States and Europe. Regulators have already approved Soliris in both locations to treat the disorder, which is called paroxysmal nocturnal hemoglobinuria. The disorder, known as PNH, is a chronic disease caused by a mutation in certain adult blood cells. It is normally treated with transfusions and bone marrow transplants. Soliris is Alexion's only commercial product. The company hopes to launch the drug commercially in Japan in 2010. Shares of Alexion rose $1.09, or 3.3 percent, to close at $34.37.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next